Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent
Investigational Drug Radium-223 Chloride Improved Overall Survival By 44 Percent
NKTR-102 Shows 29 Percent Response in Phase II Study
New Two-Step Matching Process Increases Success of Transplants
Weak Electromagnetic Fields Can Possibly Stabilize Tumors
One Flexible Sigmoidoscopy Can Reduce Risk by 31 Percent
Neurocognitive Deficits Affect Future Adult Employment
Smoking, Drinking Factors Affect Adherence to Preventive Regimen
Two Doses of the Vaccine Cervarix Can Be As Effective As Three
HPV-Positive Women Over 30 Should Be Retested Within Two Years
Clinical Trials Approved By NCI CTEP Last Month
Nucynta ER Approved For Managing Chronic Pain In Adults
Zofran Label Change Includes Warnings of QT Prolongation
Agency Approves Two Pairs Of Drugs and Diagnostic Tests
Adcetris Granted Approval For Hodgkin’s Lymphoma and ALCL
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer. - Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel - Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI
“To my knowledge, 100% of grants that clear my desk get funded” - Senthil K. Muthuswamy named director of NCI’s Center for Cancer Research
